Efficacy and Safety of Terbinafine 1% Solution in the Treatment of Interdigital Tinea Pedis and Tinea Corporis or Tinea Cruris
Lebwohl M, Elewski B, Eisen D, Savin RC, The Terbinafine 1% Solution Group (SFF-351)
Two randomized, double-blind, vehicle-controlled, multicenter studies assessed the efficacy and safety of a new terbinafine 1% solution for the treatment of interdigital tinea pedis and tinea corporis or tinea cruris (tinea corporis/cruris). Patients with interdigital tinea pedis applied terbinafine 1% solution or vehicle twice daily for 1 week with 7 weeks of follow-up (N=153), and patients with tinea corporis/cruris applied terbinafine 1% solution or vehicle once daily for 1 week with 3 weeks of follow-up (N=66). Efficacy was assessed mycologically and clinically at the end of treatment and throughout follow-up. In the tinea pedis study, 66% of patients were effectively treated with terbinafine compared with 4% of the group treated by vehicle (P<.001 mantel-haenszel test in the tinea corporis study treatment was effective of terbinafine group compared with vehicle class="article_abstract_nonital">P<.001 there were no significant differences in the frequency of cutaneous adverse events between groups either study. we conclude that one week therapy with terbinafine solution is highly effective superior to vehicle and safe for use superficial fungal infections.>